ST3
MCID: SPP010
MIFTS: 51

Suppressor of Tumorigenicity 3 (ST3)

Categories: Cancer diseases, Endocrine diseases

Aliases & Classifications for Suppressor of Tumorigenicity 3

MalaCards integrated aliases for Suppressor of Tumorigenicity 3:

Name: Suppressor of Tumorigenicity 3 56 71
Cervical Carcinoma 56 13 54 17
Cervical Carcinoma, Tumor-Suppressor Gene Involved in; Ccts 56
Cervical Carcinoma, Tumor-Suppressor Gene Involved in 56
Tumor-Suppressor Gene, Hela Cell Type; Tshl 56
Tumor-Suppressor Gene, Hela Cell Type 56
Cervix Carcinoma 71
Tshl 56
Ccts 56
St3 56

Classifications:



External Ids:

OMIM 56 191181
UMLS 71 C0302592 C1860658

Summaries for Suppressor of Tumorigenicity 3

MalaCards based summary : Suppressor of Tumorigenicity 3, also known as cervical carcinoma, is related to squamous cell papilloma and in situ carcinoma. An important gene associated with Suppressor of Tumorigenicity 3 is ST3 (Suppression Of Tumorigenicity 3), and among its related pathways/superpathways are GPCR Pathway and Cellular Senescence (REACTOME). The drugs Vaccines and Imiquimod have been mentioned in the context of this disorder. Affiliated tissues include cervix, lymph node and testes, and related phenotypes are digestive/alimentary and hematopoietic system

More information from OMIM: 191181

Related Diseases for Suppressor of Tumorigenicity 3

Diseases in the Suppressor of Tumorigenicity 3 family:

Suppressor of Tumorigenicity 11

Diseases related to Suppressor of Tumorigenicity 3 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 523)
# Related Disease Score Top Affiliating Genes
1 squamous cell papilloma 31.5 TP53 CDKN2A
2 in situ carcinoma 31.3 TP53 MYC CDKN2A
3 cervix uteri carcinoma in situ 31.1 TP53 RB1 FHIT CDKN2A
4 cervical squamous cell carcinoma 31.0 TP53 MYC CDKN2A
5 familial retinoblastoma 30.8 TP53 RB1 CDKN2A
6 cervix carcinoma 30.7 TP53 MYC FHIT CDKN2A
7 cervical adenocarcinoma 30.3 TP53 MYC CDKN2A CDKN1A
8 keratinizing squamous cell carcinoma 30.3 TP53 CDKN2A
9 papilloma 30.2 UBE3A TP53 RB1 CDKN2A CDKN1A
10 endocervical adenocarcinoma 30.0 TP53 CDKN2A CDKN1A
11 anogenital venereal wart 29.9 UBE3A TP53 CDKN2A
12 retinoblastoma 29.9 TP53 RB1 MYC CDKN2A CDKN1A
13 anal squamous cell carcinoma 29.8 TP53 CDKN2A
14 oral cancer 29.7 TP53 FHIT CDKN2A
15 soft tissue sarcoma 29.7 TP53 BCL2
16 retinitis pigmentosa 11 29.6 TP53 MYC CDKN2A
17 adenocarcinoma 29.6 TP53 RB1 MYC CDKN2A CDKN1A BCL2
18 adult t-cell leukemia 29.6 TP53 MYC CDKN2A
19 neuroblastoma 29.6 TP53 RB1 MYC CDKN2A CDKN1A
20 vaginal cancer 29.5 UBE3A TP53 CDKN2A
21 anus cancer 29.5 UBE3A TP53 CDKN2A
22 vulva cancer 29.5 TP53 CDKN2A CA9
23 skin melanoma 29.5 TP53 CDKN2A CDKN1A
24 penile cancer 29.4 UBE3A TP53 CDKN2A
25 small cell cancer of the lung 29.4 TP53 RB1 CDKN2A BCL2
26 gallbladder cancer 29.3 TP53 MYC FHIT CDKN2A
27 colon adenocarcinoma 29.1 TP53 MYC CDKN1A BCL2
28 osteogenic sarcoma 29.0 TP53 RB1 MYC CDKN2A CDKN1A
29 endometrial cancer 29.0 TP53 RB1 MYC CDKN2A CDKN1A BCL2
30 breast ductal carcinoma 29.0 TP53 CDKN1A BCL2
31 squamous cell carcinoma 28.9 TP53 RB1 MYC FHIT CDKN2A CDKN1A
32 lymphoma 28.9 TP53 RB1 MYC CDKN2A BCL2
33 rhabdomyosarcoma 28.8 TP53 RB1 MYC CDKN2A CDKN1A
34 burkitt lymphoma 28.8 TP53 MYC CDKN2A CDKN1A BCL2
35 myelodysplastic syndrome 28.7 TP53 MYC FHIT CDKN2A CDKN1A
36 ductal carcinoma in situ 28.7 TP53 MYC CDKN2A CA9
37 basal cell carcinoma 28.7 TP53 CDKN2A CDKN1A BCL2
38 b-cell lymphoma 28.7 TP53 RB1 MYC CDKN2A CDKN1A BCL2
39 leukemia, acute lymphoblastic 28.7 TP53 RB1 MYC FHIT CDKN2A BCL2
40 myeloma, multiple 28.6 TP53 MYC CDKN2A CDKN1A BCL2
41 fibrosarcoma 28.6 TP53 MYC CDKN1A CA9
42 pancreatic adenocarcinoma 28.4 TP53 MYC CDKN2A CDKN1A BCL2
43 transitional cell carcinoma 28.3 TP53 FHIT CDKN2A CDKN1A CA9
44 kidney cancer 28.3 TP53 FHIT CDKN2A CDKN1A CA9
45 glioblastoma multiforme 28.3 TP53 RB1 MYC CDKN2A CDKN1A CA9
46 lung cancer susceptibility 3 28.2 TP53 RB1 MYC FHIT CDKN2A CDKN1A
47 nasopharyngeal carcinoma 28.1 TP53 MYC CDKN2A CDKN1A CA9 BCL2
48 pancreatic cancer 27.9 TP53 RB1 MYC FHIT CDKN2A CDKN1A
49 esophageal cancer 27.9 TP53 RB1 MYC FHIT CDKN2A CDKN1A
50 cervical cancer 27.8 UBE3A TP53 TAP1 RB1 MYC FHIT

Graphical network of the top 20 diseases related to Suppressor of Tumorigenicity 3:



Diseases related to Suppressor of Tumorigenicity 3

Symptoms & Phenotypes for Suppressor of Tumorigenicity 3

Clinical features from OMIM:

191181

MGI Mouse Phenotypes related to Suppressor of Tumorigenicity 3:

45 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 10.1 BCL2 CA9 CDKN1A CDKN2A FHIT MYC
2 hematopoietic system MP:0005397 10.09 BCL2 CA9 CDKN1A CDKN2A FHIT MYC
3 endocrine/exocrine gland MP:0005379 10.08 BCL2 CA9 CDKN1A CDKN2A MYC RB1
4 immune system MP:0005387 10.06 BCL2 CA9 CDKN1A CDKN2A FHIT MYC
5 integument MP:0010771 10.02 BCL2 CDKN1A CDKN2A FHIT MYC RB1
6 mortality/aging MP:0010768 10.02 BCL2 CA9 CDKN1A CDKN2A FHIT MYC
7 adipose tissue MP:0005375 9.99 BCL2 CDKN1A MYC PLIN3 RB1 TP53
8 hearing/vestibular/ear MP:0005377 9.85 BCL2 CDKN1A MYC RB1 TP53
9 neoplasm MP:0002006 9.76 BCL2 CDKN1A CDKN2A FHIT MYC RB1
10 muscle MP:0005369 9.73 BCL2 CDKN1A CDKN2A MYC RB1 TP53
11 no phenotypic analysis MP:0003012 9.43 CDKN1A CDKN2A MYC RB1 TP53 UBE3A
12 pigmentation MP:0001186 9.02 BCL2 CDKN2A MYC RB1 TP53

Drugs & Therapeutics for Suppressor of Tumorigenicity 3

Drugs for Suppressor of Tumorigenicity 3 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 211)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Vaccines Phase 4
2
Imiquimod Approved, Investigational Phase 2, Phase 3 99011-02-6 57469
3
Metronidazole Approved Phase 2, Phase 3 443-48-1 4173
4
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
5
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
6
Gemcitabine Approved Phase 3 95058-81-4 60750
7
Nelfinavir Approved Phase 3 159989-64-7 64143
8
Pemetrexed Approved, Investigational Phase 3 137281-23-3, 150399-23-8 60843 446556
9
Topotecan Approved, Investigational Phase 3 123948-87-8, 119413-54-6 60700
10
Cemiplimab Approved, Investigational Phase 3 1801342-60-8
11
Irinotecan Approved, Investigational Phase 3 97682-44-5, 100286-90-6 60838
12
Atezolizumab Approved, Investigational Phase 3 1380723-44-3
13
Bevacizumab Approved, Investigational Phase 3 216974-75-3
14
Ondansetron Approved Phase 3 99614-02-5 4595
15
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
16
Carboplatin Approved Phase 3 41575-94-4 10339178 38904 498142
17
Vinorelbine Approved, Investigational Phase 3 71486-22-1 60780 44424639
18
Progesterone Approved, Vet_approved Phase 3 57-83-0 5994
19
Cisplatin Approved Phase 3 15663-27-1 2767 441203 84093
20
Inulin Approved, Investigational, Nutraceutical Phase 3 9005-80-5 24763
21
Vitamin D3 Approved, Nutraceutical Phase 3 67-97-0 5280795 6221
22
Vitamin D Approved, Nutraceutical, Vet_approved Phase 3 1406-16-2
23
Nimotuzumab Investigational Phase 3 828933-61-3, 780758-10-3
24
Tirapazamine Investigational Phase 3 27314-97-2
25 Radiopharmaceuticals Phase 3
26 Endostar protein Phase 3
27 Endostatins Phase 3 71581480
28 Immunologic Factors Phase 3
29 Antineoplastic Agents, Immunological Phase 3
30 Immunosuppressive Agents Phase 3
31 Antimetabolites Phase 3
32 Tubulin Modulators Phase 3
33 Antimitotic Agents Phase 3
34 Immunoglobulins Phase 3
35 Antibodies Phase 3
36 Anti-Bacterial Agents Phase 2, Phase 3
37 Antibodies, Monoclonal Phase 3
38 Adjuvants, Immunologic Phase 2, Phase 3
39 glucocorticoids Phase 3
40 Anti-Inflammatory Agents Phase 3
41 interferons Phase 2, Phase 3
42 Gastrointestinal Agents Phase 3
43 Immunoglobulins, Intravenous Phase 3
44 Mitogens Phase 3
45 Endothelial Growth Factors Phase 3
46 Immunoglobulin G Phase 3
47 Antiparasitic Agents Phase 2, Phase 3
48 Antiprotozoal Agents Phase 2, Phase 3
49 Antineoplastic Agents, Hormonal Phase 3
50 Antiemetics Phase 3

Interventional clinical trials:

(show top 50) (show all 198)
# Name Status NCT ID Phase Drugs
1 Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease Completed NCT00815282 Phase 4
2 A Multicenter, Randomized Controlled Clinical Trial Comparing Endostar With Concurrent Chemoradiotherapy Versus Concurrent Chemoradiotherapy in the Treatment of Locally Advanced Cervical Carcinoma Unknown status NCT03086681 Phase 3 Endostar;DDP
3 Concurrent Chemoradiotherapy With Weekly Cisplatin Versus Concurrent Chemoradiotherapy With Weekly Cisplatin and Paclitaxel in Locally Advanced Carcinoma Cervix Unknown status NCT01593306 Phase 3 Paclitaxel, Cisplatin;Cisplatin
4 Phase III Randomized Trial of Comparing Chemoradiotherapy vs. Radiotherapy Alone in Lymph Node Negative Patients With Early-Stage Cervical Cancer Following Radical Hysterectomy Unknown status NCT01756170 Phase 3 paclitaxel;cisplatin
5 Phase III Randomized Study of Concurrent Paclitaxel/Cisplatin Chemotherapy and Radiotherapy With or Without Consolidation Chemotherapy in High-Risk Patients With Early-Stage Cervical Cancer Following Radical Hysterectomy Unknown status NCT01755845 Phase 3 paclitaxel;cisplatin
6 Comparing Standard Concurrent Chemo-radiation to Neoadjuvant Chemotherapy Then Surgery or Radiation in Patients Stage Ib2-early IIb Cervical Carcinoma Unknown status NCT01000415 Phase 3
7 A Phase III Randomized Trial of FDG-PET in the Management of Advanced Cervical Cancer With Enlarged Pelvic Lymph Node on MRI Image Unknown status NCT00146458 Phase 3
8 A Double-blind Placebo-controlled Trial of Dietary Supplementation With 15g/Day FOS for Five Weeks in Patients With Endometrial/Cervical Carcinoma or 7.5 Weeks in Patients With Prostate Carcinoma Undergoing Pelvic Radiotherapy. Unknown status NCT01414517 Phase 3
9 A Randomized, Single Blinded Trial to Evaluate the Efficacy of Imiquimod in Women With Residual/Recurrent Cervical Intraepithelial Neoplasia (CIN) After Previous Treatment Unknown status NCT02669459 Phase 3 Imiquimod
10 Collaborative Corneal Transplantation Studies (CCTS) Completed NCT00000137 Phase 3
11 Phase III Study of S-1 + Cisplatin Compared With Single-agent Cisplatin in Stage IVB, Recurrent, or Persistent Carcinoma of the Cervix Completed NCT00770874 Phase 3 S-1 + Cisplatin (arm A);Cisplatin (arm B)
12 A Randomized Phase III Trial Of Paclitaxel Plus Cisplatin Versus Vinorelbine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Versus Topotecan Plus Cisplatin In Stage IVB, Recurrent Or Persistent Carcinoma of the Cervix Completed NCT00064077 Phase 3 Cisplatin;Gemcitabine Hydrochloride;Paclitaxel;Topotecan Hydrochloride;Vinorelbine Tartrate
13 A Randomized Phase III Trial of Cisplatin Plus Paclitaxel With and Without NCI-Supplied Bevacizumab (NSC #704865) Versus the Non-platinum Doublet, Topotecan Plus Paclitaxel, With and Without NCI-Supplied Bevacizumab, in Stage IVB, Recurrent or Persistent Carcinoma of the Cervix Completed NCT00803062 Phase 3 Cisplatin;Paclitaxel;Topotecan Hydrochloride
14 Phase 3 Randomized Controlled Trial of Non-inferiority of Topical Imiquimod vs. LEEP for Women With Carcinoma In-situ of the Cervix Completed NCT02130323 Phase 2, Phase 3 Imiquimod
15 A Randomized Clinical Trial of Radiotherapy and Metronidazole Versus Radiotherapy Alone in Anaemic Patients With Advanced Cervical Cancer In Mulago Completed NCT01937650 Phase 2, Phase 3 Radiotherapy plus metronidazole
16 Preoperative Dexamethasone Reduces Postoperative Pain, Nausea and Vomiting Following Mastectomy for Breast Cancer. Completed NCT01116713 Phase 3 intravenous dexamethasone;Homologated placebo.
17 Phase III Clinical Trial: "Evaluation of the Combination of Nimotuzumab and Cisplatin-Vinorelbine in First Line Chemotherapy in the Survival of Patients With Recurring-Persistent Cervical Carcinoma" Completed NCT02083211 Phase 3 mAb Nimotuzumab
18 Neoadjuvant Chemotherapy and Radical Surgery Versus Concurrent Chemoirradiation in FIGO Stage IIB Cervical Cancer Recruiting NCT02595554 Phase 3 Paclitaxel;Cisplatin
19 An Open-Label, Randomized, Phase 3 Clinical Trial of REGN2810 Versus Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Carcinoma Recruiting NCT03257267 Phase 3 Cemiplimab;Investigator Choice (IC) Chemotherapy
20 A Randomized Phase III Trial of Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab Versus Platinum Chemotherapy Plus Paclitaxel and Bevacizumab in Metastatic (Stage IVB), Persistent, or Recurrent Carcinoma of the Cervix Recruiting NCT03556839 Phase 3 Atezolizumab;Bevacizumab;Cisplatin;Paclitaxel
21 Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy With or Without Adjuvant Chemotherapy in High-Risk Patients With Early-Stage Cervical Carcinoma Following Radical Hysterectomy Recruiting NCT00980954 Phase 3 carboplatin;cisplatin;paclitaxel
22 A Trial of Neoadjuvant Chemotherapy Followed by Surgery Versus Surgery in FIGO IB2 and IIA2 Cervical Cancer(CSEM005) Recruiting NCT02629718 Phase 3 NACT (Paclitaxel + Cisplatin or carboplatin)
23 A Phase III Randomized Clinical Trial to Study the Radiosensitizing Effect of Nelfinavir in Locally Advanced Carcinoma of Uterine Cervix. Recruiting NCT03256916 Phase 3 Nelfinavir;Cisplatin
24 Randomized Phase III Clinical Trial of Weekly Versus Tri-weekly Cisplatin Based Chemoradiation in Locally Advanced Cervical Cancer Recruiting NCT01561586 Phase 3 Weekly cisplatin with RT;Tri-weekly cisplatin with RT
25 Phase II/III Clinical Trial of Intensity Modulated Radiation Therapy With Concurrent Cisplatin for Stage I-IVA Cervical Carcinoma Active, not recruiting NCT01554397 Phase 2, Phase 3 Cisplatin
26 Multicenter Randomised Double-blind Study to Compare HR3 or Placebo in Combination With Cisplatin-navelbine for Patients With Cervical Carcinoma, Followed in Case of Progression by a Second Line. Active, not recruiting NCT03413579 Phase 3
27 Comparison of Different Adjuvant Treatments Following Radical Surgery in Early Stage Cervical Carcinoma Active, not recruiting NCT00806117 Phase 3
28 Randomized Controlled Trial of Neo-adjuvant Progesterone and Vitamin D3 in Women With Large Operable Breast Cancer and Locally Advanced Breast Cancer. Active, not recruiting NCT01608451 Phase 3 Cholecalciferol;Inj. Progesterone
29 A Phase III, Randomized Trial of Weekly Cisplatin and Radiation Versus Cisplatin and Tirapazamine and Radiation in Stage IB2, IIA, IIIB and IVA Cervical Carcinoma Limited to the Pelvis Terminated NCT00262821 Phase 3 cisplatin;tirapazamine
30 Phase II, Prospective, Randomized, Non-comparative Study of Treatment With Induction Chemotherapy With Cisplatin and Gemcitabine Followed by Chemoradiation or Definitive Chemoradiation in Invasive Locally Advanced Carcinomas of Uterine Cervix. Unknown status NCT01973101 Phase 2 Cisplatin;Gemcitabine;cisplatin
31 Vaccination of Patients With Advanced Melanoma, Pancreatic, Colon and Cervical Cancer With HLA-A1, -A2 and -B35 Restricted Survivin Peptides Unknown status NCT00108875 Phase 1, Phase 2
32 An Exploratory Pharmacogenomic Study of Neoadjuvant Cetuximab Followed by Cisplatin, Radiotherapy, and Cetuximab in Women With Newly Diagnosed Locally Advanced or Metastatic Cervical Carcinoma Unknown status NCT00292955 Phase 2 Cetuximab
33 An Open Label Randomized Phase 2, Pilot Study to Investigate the Effectiveness of Palliative Chemotherapy in Stage IVB, Recurrent or Persistent Carcinoma Cervix Unknown status NCT02492503 Phase 1, Phase 2 Paclitaxel and carboplatin;Paclitaxel and carboplatin
34 Phase II Study of NESP (Novel Erythropoiesis Stimulating Protein) During Concurrent Chemo-Radiation for the Treatment of Cervical Carcinoma. Unknown status NCT00039884 Phase 2 NESP - Novel Erythropoiesis Stimulating Protein
35 Phase II Study Evaluating the Role of Tomotherapy- Based Intensity Modulated Radiotherapy and Brachytherapy in Postsurgery Recurrent Carcinoma Cervix Unknown status NCT01117402 Phase 2
36 A Phase II Study of the Association of Glivec® (Imatinib Mesylate, Formerly Known as STI 571) Plus Gemzar® (Gemcitabine) in Patients With Unresectable, Refractory, Malignant Mesothelioma Expressing Either PDGFR-Beta or C-Kit Unknown status NCT00551252 Phase 2 Imatinib mesylate plus Gemcitabine
37 HepaSphere Interventional Therapy Using Digital Subtraction Angiography(DSA) for Cervical Carcinoma: Clinical Trial Completed NCT02523365 Phase 1, Phase 2
38 A Phase II Evaluation Of OSI-774 (NSC #718781) In The Treatment Of Persistent or Recurrent Squamous Cell Carcinoma Of The Cervix Completed NCT00031993 Phase 2 erlotinib hydrochloride
39 A Phase II Study of Arsenic Trioxide (NSC #706363) in Patients With Advanced Cervical Carcinoma Completed NCT00005999 Phase 2 arsenic trioxide
40 A Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Advanced Cervical Carcinoma Completed NCT00005070 Phase 2 irofulven
41 Phase I/II Study of Gemcitabine and Concurrent Radiation Followed by Adjuvant Hysterectomy in Bulky Stage Ib and IIa Cervical Carcinoma: Analysis of Prognostic Factors and Determinants of Response: A Pilot Study Completed NCT00184093 Phase 1, Phase 2 Gemcitabine
42 A Phase II Trial of Capecitabine and Docetaxel in the Treatment of Advanced and Recurrent Cervical Cancer Completed NCT00257348 Phase 2 Capecitabine;Docetaxel
43 Single-center Phase I/II Trial of Sodium Oxybate in Patients With Alternating Hemiplegia of Childhood (AHC-SO Trial) Completed NCT00931164 Phase 1, Phase 2 Sodium Oxybate
44 A Phase II Evaluation Of Docetaxel (NSC #628503) In The Treatment Of Persistent Or Recurrent Squamous Cell Carcinoma Of The Cervix Completed NCT00041093 Phase 2 Docetaxel
45 PHASE 1-2 STUDY EVALUATING HIGH DOSE ADXS11-001 (1 x 10^10 CFU) TREATMENT IN WOMEN WITH HPV+ CARCINOMA OF THE CERVIX Completed NCT02164461 Phase 1, Phase 2
46 Phase I/IIA, Open-Label, Safety, Tolerability, and Immunogenicity Study of INO-3112 Delivered by Electroporation (EP) in Women With Cervical Cancer After Chemoradiation for Newly Diagnosed Disease or Therapy for Recurrent and/or Persistent Disease Completed NCT02172911 Phase 1, Phase 2
47 A Phase II Evaluation of ABI-007 in the Treatment of Persistent or Recurrent Squamous or Nonsquamous Cell Carcinoma of the Cervix Completed NCT00309959 Phase 2 Paclitaxel Albumin-Stabilized Nanoparticle Formulation
48 A Phase II Evaluation of Cetuximab (Erbitux®, C225, NSC# 714692) in the Treatment of Persistent or Recurrent Squamous or Non-Squamous Cell Carcinoma of the Cervix Completed NCT00499031 Phase 2
49 Neoadjuvant Chemotherapy With Docetaxel in Advanced Cervical Carcinoma Completed NCT00003445 Phase 2 docetaxel
50 A Phase II Study of Temsirolimus (NSC 683864), an mTOR Inhibitor, in Patients With Recurrent, Unresectable, Locally Advanced or Metastatic Carcinoma of the Cervix Completed NCT01026792 Phase 2 Temsirolimus

Search NIH Clinical Center for Suppressor of Tumorigenicity 3

Genetic Tests for Suppressor of Tumorigenicity 3

Anatomical Context for Suppressor of Tumorigenicity 3

MalaCards organs/tissues related to Suppressor of Tumorigenicity 3:

40
Cervix, Lymph Node, Testes, Breast, Uterus, T Cells, Endothelial

Publications for Suppressor of Tumorigenicity 3

Articles related to Suppressor of Tumorigenicity 3:

(show top 50) (show all 10543)
# Title Authors PMID Year
1
Interstitial deletion of 11q13 sequences in HeLa cells. 61 56
10959095 2000
2
Deletion and translocation of chromosome 11q13 sequences in cervical carcinoma cell lines. 61 56
7887426 1995
3
Loss of heterozygosity in cervical carcinoma: subchromosomal localization of a putative tumor-suppressor gene to chromosome 11q22-q24. 61 56
8041728 1994
4
Loss of heterozygosity for alleles on chromosome II in cervical carcinoma. 56 61
1680288 1991
5
Genetic characteristics of the HeLa cell. 56 61
1246620 1976
6
Cell culture forensics. 56
11438719 2001
7
Short tandem repeat profiling provides an international reference standard for human cell lines. 56
11416159 2001
8
East Hela and West Hela, in memory of Stella Mamaeva, 1939-1995. 56
8964054 1996
9
Localization of HeLa cell tumor-suppressor gene to the long arm of chromosome II. 56
2577469 1989
10
Implication of chromosome 11 in the suppression of neoplastic expression in human cell hybrids. 56
2877730 1986
11
Introduction of human chromosome 11 via microcell transfer controls tumorigenic expression of HeLa cells. 56
2881780 1986
12
Suppression of tumorigenicity in somatic cell hybrids. III. Cosegregation of human chromosome 11 of a normal cell and suppression of tumorigenicity in intraspecies hybrids of normal diploid x malignant cells. 56
3956263 1986
13
Suppression of tumorigenicity. 56
7140370 1982
14
Specific chromosome loss associated with the expression of tumorigenicity in human cell hybrids. 56
7323948 1981
15
Cross-contamination of cells in culture. 56
6451928 1981
16
Characteristics of HeLa strains: permanent vs. variable features. 56
7002488 1980
17
Suppression of tumorigenicity in somatic cell hybrids. I. Suppression and reexpression of tumorigenicity in diploid human X D98AH2 hybrids and independent segregation of tumorigenicity from other cell phenotypes. 56
6934067 1980
18
Suppression of malignancy in human cells. 56
1264187 1976
19
HeLa cultures defined. 56
1246601 1976
20
Banded marker chromosomes as indicators of intraspecies cellular contamination. 56
4469665 1974
21
George Otto Gey. (1899-1970). The HeLa cell and a reappraisal of its origin. 56
4942173 1971
22
Apparent Hela cell contamination of human heteroploid cell lines. 56
5641128 1968
23
MicroRNA-34a suppresses invasion through downregulation of Notch1 and Jagged1 in cervical carcinoma and choriocarcinoma cells. 54 61
20351093 2010
24
Increased cytotoxicity of an unusual DNA topoisomerase II inhibitor compound C-1305 toward HeLa cells with downregulated PARP-1 activity results from re-activation of the p53 pathway and modulation of mitotic checkpoints. 54 61
20067769 2010
25
Vascular endothelial growth factor C promotes cervical cancer metastasis via up-regulation and activation of RhoA/ROCK-2/moesin cascade. 61 54
20429915 2010
26
Rescue of p53 function by small-molecule RITA in cervical carcinoma by blocking E6-mediated degradation. 61 54
20395210 2010
27
HER2 codon 655 polymorphism is associated with advanced uterine cervical carcinoma. 54 61
20026098 2010
28
Constitutive HIF-1 activity in malignant melanoma. 54 61
20185296 2010
29
Notch1 regulates the functional contribution of RhoC to cervical carcinoma progression. 61 54
19953094 2010
30
Wogonin induces G1 phase arrest through inhibiting Cdk4 and cyclin D1 concomitant with an elevation in p21Cip1 in human cervical carcinoma HeLa cells. 54 61
19935879 2009
31
Overexpression of phosphorylated 4E-BP1 predicts for tumor recurrence and reduced survival in cervical carcinoma treated with postoperative radiotherapy. 54 61
19362787 2009
32
[Involvement of human papillomavirus in upper aero-digestive tracts cancers]. 61 54
19744917 2009
33
HER2/neu (c-erbB-2) gene amplification and protein expression are rare in uterine cervical neoplasia: a tissue microarray study of 814 archival specimens. 61 54
19775342 2009
34
Identification of an active site of EMMPRIN for the augmentation of matrix metalloproteinase-1 and -3 expression in a co-culture of human uterine cervical carcinoma cells and fibroblasts. 54 61
19427027 2009
35
The role of VEGF-C/D and Flt-4 in the lymphatic metastasis of early-stage invasive cervical carcinoma. 61 54
19589137 2009
36
Antitumor activity of small double-stranded oligodeoxynucleotides targeting telomerase RNA in malignant melanoma cells. 54 61
19441892 2009
37
The association of XRCC1 gene single nucleotide polymorphisms with response to neoadjuvant chemotherapy in locally advanced cervical carcinoma. 54 61
19563645 2009
38
Spatiotemporal activation of caspase-dependent and -independent pathways in staurosporine-induced apoptosis of p53wt and p53mt human cervical carcinoma cells. 54 61
19216720 2009
39
[Inhibitive effect of E1A gene on the cell growth of human cervical carcinoma cell in vitro]. 54 61
19483289 2009
40
The association between the survivin C-31G polymorphism and gastric cancer risk in a Chinese population. 61 54
18716870 2009
41
Single nucleotide polymorphisms in antigen processing machinery component ERAP1 significantly associate with clinical outcome in cervical carcinoma. 61 54
19202550 2009
42
Expressions of IGFBP-5, cFLIP in cervical intraepithelial neoplasia, cervical carcinoma and their clinical significances: a molecular pathology. 54 61
19476635 2009
43
No association of TAP1 and TAP2 genes polymorphism with risk of cervical cancer in north Indian population. 61 54
19263211 2009
44
Identification of novel fibroblast growth factor receptor 3 gene mutations in actinic cheilitis and squamous cell carcinoma of the lip. 54 61
19327639 2009
45
Immunohistochemical studies of trophoblastic tumors. 61 54
19145204 2009
46
Differential tissue-specific protein markers of vaginal carcinoma. 61 54
19367286 2009
47
Major vault protein may affect nonhomologous end-joining repair and apoptosis through Ku70/80 and bax downregulation in cervical carcinoma tumors. 61 54
19251084 2009
48
Mutation of PIK3CA: possible risk factor for cervical carcinogenesis in older women. 61 54
19148475 2009
49
Preliminary study of TIP47 as a possible new biomarker of cervical dysplasia and invasive carcinoma. 54 61
19331227 2009
50
Transition of cervical carcinoma in situ to invasive cancer: role of p16 INK4a expression in progression and in recurrence. 61 54
19100258 2009

Variations for Suppressor of Tumorigenicity 3

Expression for Suppressor of Tumorigenicity 3

Search GEO for disease gene expression data for Suppressor of Tumorigenicity 3.

Pathways for Suppressor of Tumorigenicity 3

Pathways related to Suppressor of Tumorigenicity 3 according to GeneCards Suite gene sharing:

(show top 50) (show all 56)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.62 UBE3A TP53 RB1 MYC CDKN2A CDKN1A
2
Show member pathways
13.06 TP53 RB1 CDKN2A CDKN1A CA9
3
Show member pathways
12.99 TP53 RB1 MYC CDKN1A BCL2
4
Show member pathways
12.95 UBE3A TP53 RB1 MYC CDKN1A BCL2
5
Show member pathways
12.86 TP53 TAP1 RB1 MYC CDKN2A CDKN1A
6
Show member pathways
12.84 TP53 RB1 MYC CDKN2A CDKN1A BCL2
7 12.81 TP53 RB1 MYC CDKN2A CDKN1A BCL2
8
Show member pathways
12.78 TP53 TAP1 RB1 MYC CDKN1A BCL2
9
Show member pathways
12.72 TP53 RB1 MYC CDKN2A CDKN1A BCL2
10
Show member pathways
12.67 TP53 RB1 MYC CDKN1A BCL2
11
Show member pathways
12.67 TP53 MYC CDKN2A CDKN1A BCL2
12
Show member pathways
12.62 TP53 RB1 FHIT CDKN2A CDKN1A BCL2
13
Show member pathways
12.56 TP53 MYC CDKN1A BCL2
14
Show member pathways
12.55 TP53 RB1 MYC CDKN2A CDKN1A
15
Show member pathways
12.53 TP53 MYC CDKN1A BCL2
16 12.52 TP53 MYC CDKN2A CDKN1A BCL2
17 12.47 TP53 RB1 CDKN2A CDKN1A
18 12.35 TP53 RB1 MYC CDKN2A CDKN1A
19
Show member pathways
12.33 TP53 RB1 CDKN2A CDKN1A
20 12.32 TP53 RB1 MYC CDKN2A CDKN1A
21
Show member pathways
12.28 TP53 RB1 MYC CDKN2A CDKN1A BCL2
22 12.27 UBE3A TP53 RB1 CDKN2A CDKN1A
23
Show member pathways
12.24 TP53 RB1 CDKN1A BCL2
24
Show member pathways
12.22 TP53 RB1 MYC CDKN1A BCL2
25
Show member pathways
12.21 RB1 MYC CDKN2A CDKN1A
26 12.14 TP53 RB1 MYC BCL2
27 12.13 TP53 RB1 MYC CDKN2A CDKN1A
28 12.11 TP53 MYC CDKN1A
29 12.03 TP53 TAP1 RB1 CDKN1A BCL2
30 12.01 TP53 MYC CDKN1A
31 11.98 TP53 MYC CDKN1A BCL2
32 11.96 TP53 RB1 MYC
33 11.95 TP53 MYC CDKN2A CDKN1A BCL2
34 11.92 TP53 RB1 MYC CDKN2A CDKN1A
35 11.88 TP53 RB1 CDKN2A CDKN1A BCL2
36 11.85 TP53 RB1 MYC CDKN1A
37 11.83 UBE3A RB1 CDKN1A
38 11.76 MYC CDKN1A BCL2
39 11.73 TP53 CDKN2A CDKN1A BCL2
40 11.72 RB1 MYC CDKN1A
41 11.64 MYC CDKN1A BCL2
42 11.63 TP53 RB1 MYC CDKN2A CDKN1A
43 11.56 TP53 MYC CDKN1A
44 11.55 TP53 MYC CDKN1A
45 11.53 RB1 MYC CDKN1A
46 11.53 UBE3A TP53 RB1 CDKN2A CDKN1A BCL2
47 11.47 TP53 MYC CDKN1A
48 11.4 TP53 RB1 MYC FHIT CDKN1A BCL2
49 11.36 TP53 RB1 CDKN2A CDKN1A BCL2
50 11.22 TP53 RB1 MYC CDKN1A BCL2

GO Terms for Suppressor of Tumorigenicity 3

Biological processes related to Suppressor of Tumorigenicity 3 according to GeneCards Suite gene sharing:

(show all 31)
# Name GO ID Score Top Affiliating Genes
1 apoptotic process GO:0006915 9.99 TP53 RB1 FHIT CDKN2A BCL2
2 negative regulation of cell proliferation GO:0008285 9.92 TP53 RB1 CDKN2A CDKN1A BCL2
3 negative regulation of gene expression GO:0010629 9.88 TP53 RB1 MYC CDKN1A
4 cytokine-mediated signaling pathway GO:0019221 9.87 TP53 MYC CDKN1A BCL2
5 rhythmic process GO:0048511 9.81 UBE3A TP53 ENOX2
6 response to drug GO:0042493 9.8 TP53 MYC CDKN1A CA9 BCL2
7 cellular response to hypoxia GO:0071456 9.79 TP53 MYC BCL2
8 regulation of cell cycle GO:0051726 9.78 TP53 RB1 CDKN1A BCL2
9 regulation of mitotic cell cycle GO:0007346 9.76 RB1 MYC CDKN1A
10 ovarian follicle development GO:0001541 9.69 UBE3A MYC BCL2
11 neuron apoptotic process GO:0051402 9.67 TP53 RB1 BCL2
12 G1/S transition of mitotic cell cycle GO:0000082 9.67 RB1 MYC CDKN2A CDKN1A
13 cellular senescence GO:0090398 9.65 CDKN2A CDKN1A
14 negative regulation of reactive oxygen species metabolic process GO:2000378 9.65 TP53 BCL2
15 release of cytochrome c from mitochondria GO:0001836 9.64 TP53 BCL2
16 positive regulation of smooth muscle cell migration GO:0014911 9.63 MYC BCL2
17 response to X-ray GO:0010165 9.63 TP53 CDKN1A
18 negative regulation of mitotic cell cycle GO:0045930 9.63 TP53 RB1 BCL2
19 apoptotic mitochondrial changes GO:0008637 9.62 CDKN2A BCL2
20 Ras protein signal transduction GO:0007265 9.62 TP53 RB1 CDKN2A CDKN1A
21 mitotic cell cycle arrest GO:0071850 9.61 TP53 CDKN1A
22 negative regulation of phosphorylation GO:0042326 9.61 CDKN2A CDKN1A
23 response to gamma radiation GO:0010332 9.61 TP53 MYC BCL2
24 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.6 TP53 CDKN1A
25 T cell lineage commitment GO:0002360 9.56 TP53 BCL2
26 signal transduction by p53 class mediator GO:0072331 9.55 TP53 CDKN1A
27 B cell lineage commitment GO:0002326 9.54 TP53 BCL2
28 negative regulation of G1/S transition of mitotic cell cycle GO:2000134 9.46 RB1 CDKN2A CDKN1A BCL2
29 replicative senescence GO:0090399 9.43 TP53 CDKN2A CDKN1A
30 cell cycle arrest GO:0007050 9.35 TP53 RB1 MYC CDKN2A CDKN1A
31 negative regulation of cell growth GO:0030308 9.02 TP53 RB1 CDKN2A CDKN1A BCL2

Molecular functions related to Suppressor of Tumorigenicity 3 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transcription factor binding GO:0008134 9.35 TP53 RB1 MYC CDKN2A BCL2
2 disordered domain specific binding GO:0097718 9.33 TP53 RB1 CDKN2A
3 core promoter sequence-specific DNA binding GO:0001046 9.32 TP53 MYC
4 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 9.26 CDKN2A CDKN1A
5 ubiquitin protein ligase binding GO:0031625 9.02 TP53 RB1 FHIT CDKN1A BCL2

Sources for Suppressor of Tumorigenicity 3

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....